Skip to Content

Jazz Pharmaceuticals PLC JAZZ

Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Contact
Waterloo Road, Fifth Floor, Waterloo Exchange
Dublin, D04 E5W7, Ireland
T +353 16347800
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 1,940